ES2264145T3 - Metodos y composiciones para el tratamiento de cancer. - Google Patents

Metodos y composiciones para el tratamiento de cancer.

Info

Publication number
ES2264145T3
ES2264145T3 ES96942100T ES96942100T ES2264145T3 ES 2264145 T3 ES2264145 T3 ES 2264145T3 ES 96942100 T ES96942100 T ES 96942100T ES 96942100 T ES96942100 T ES 96942100T ES 2264145 T3 ES2264145 T3 ES 2264145T3
Authority
ES
Spain
Prior art keywords
use according
tumor
cells
expression
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96942100T
Other languages
English (en)
Spanish (es)
Inventor
Gary L. Clayman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
University of Texas at Austin
Original Assignee
University of Texas System
University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System, University of Texas at Austin filed Critical University of Texas System
Application granted granted Critical
Publication of ES2264145T3 publication Critical patent/ES2264145T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES96942100T 1995-11-30 1996-11-27 Metodos y composiciones para el tratamiento de cancer. Expired - Lifetime ES2264145T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US781095P 1995-11-30 1995-11-30
US7810P 1995-11-30

Publications (1)

Publication Number Publication Date
ES2264145T3 true ES2264145T3 (es) 2006-12-16

Family

ID=21728237

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96942100T Expired - Lifetime ES2264145T3 (es) 1995-11-30 1996-11-27 Metodos y composiciones para el tratamiento de cancer.

Country Status (19)

Country Link
US (3) US20020077313A1 (enExample)
EP (1) EP0863984B1 (enExample)
JP (1) JP2000501394A (enExample)
KR (1) KR19990071795A (enExample)
CN (2) CN101028523A (enExample)
AT (1) ATE325872T1 (enExample)
AU (1) AU722042B2 (enExample)
CA (1) CA2238829A1 (enExample)
CZ (1) CZ296810B6 (enExample)
DE (1) DE69636120T2 (enExample)
DK (1) DK0863984T3 (enExample)
ES (1) ES2264145T3 (enExample)
HU (1) HUP9902068A3 (enExample)
NO (1) NO982481L (enExample)
NZ (1) NZ324168A (enExample)
PL (1) PL186018B1 (enExample)
RU (1) RU2174409C2 (enExample)
SK (1) SK70598A3 (enExample)
WO (1) WO1997020047A1 (enExample)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU732703B2 (en) * 1996-11-20 2001-04-26 Crucell Holland B.V. An improved method for the production and purification of adenoviral vectors
US6689600B1 (en) * 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
RU2219553C2 (ru) * 2001-10-18 2003-12-20 Ростовский научно-исследовательский онкологический институт Способ определения эффективности аутогемохимиотерапии рака ректосигмоидного отдела прямой кишки и сигмовидной кишки, а также аутогемохимиотерапии в сочетании с свч-гипертермией рака прямой кишки
GB0212046D0 (en) * 2002-05-24 2002-07-03 Glaxo Group Ltd Vaccines
WO2004020971A2 (en) * 2002-08-28 2004-03-11 Introgen Therapeutics Inc. Chromatographic methods for adenovirus purification
US20050032728A1 (en) * 2002-12-17 2005-02-10 Sidney Kimmel Cancer Center Tumor suppression through bicistronic co-expression of p53 and p14ARF
CA2511535A1 (en) * 2002-12-27 2004-07-22 Introgen Therapeutics, Inc. P53 treatment of papillomavirus and carcinogen-transformed cells in hyperplastic lesions
US7534427B2 (en) * 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
RU2392319C2 (ru) * 2003-03-06 2010-06-20 Жаохи ПЕНГ Рекомбинантный вирус, построенный с использованием вектора вируса и гена-подавителя опухоли человека, а также его применение
RU2234099C1 (ru) * 2003-03-18 2004-08-10 Российская медицинская академия последипломного образования Способ дифференциальной диагностики стадий канцерогенеза
RU2242936C1 (ru) * 2003-04-21 2004-12-27 Ростовский научно-исследовательский онкологический институт Способ лечения рака легкого
EP2228452B1 (en) * 2004-02-23 2014-07-16 Novartis AG P53 wild-type as biomarker for the treatment with mtor inhibitors in combination with a cytotoxic agent
CA2557326A1 (en) * 2004-02-24 2005-09-09 Introgen Therapeutics, Inc. Combination of ad-p53 and chemotherapy for the treatment of tumours
CN100333797C (zh) * 2005-01-26 2007-08-29 彭朝晖 重组腺病毒p53制品在肿瘤治疗中的新用途
RU2245551C1 (ru) * 2004-04-23 2005-01-27 Белохвостов Александр Сергеевич Способ диагностики онкологических заболеваний
RU2263494C1 (ru) * 2004-06-08 2005-11-10 ГУ НИИ глазных болезней РАМН Способ моделирования меланомы роговицы
RU2410098C2 (ru) * 2004-08-31 2011-01-27 Новартис Аг Применение мидостаурина для лечения желудочно-кишечных стромальных опухолей
EP1679065A1 (en) 2005-01-07 2006-07-12 OctoPlus Sciences B.V. Controlled release compositions for interferon based on PEGT/PBT block copolymers
MX2007008768A (es) * 2005-01-21 2007-10-19 Genentech Inc Dosificacion fija de anticuerpos her.
WO2006081510A2 (en) * 2005-01-27 2006-08-03 Novartis Vaccines And Diagnostics Inc. Methods for treating renal cell carcinoma
CN101163984A (zh) * 2005-05-06 2008-04-16 奥索瑟夫特公司 用于跟踪对象的rf系统
US20070231304A1 (en) * 2006-01-30 2007-10-04 Introgen Therapeutics, Inc. Prognostic factors for anti-hyperproliferative disease gene therapy
EP2426142A3 (en) 2006-10-16 2012-06-13 Genelux Corporation Modified vaccinia virus strains for use in a diagnostic and therapeutic method
WO2008106646A2 (en) * 2007-03-01 2008-09-04 Introgen Therapeutics, Inc Methods and formulations for topical gene therapy
US20090081639A1 (en) * 2007-05-31 2009-03-26 Phil Hill Assay for sensitivity to chemotherapeutic agents
RU2371202C2 (ru) * 2007-07-30 2009-10-27 Государственное учреждение научно-исследовательский институт онкологии Томского Научного центра Сибирского отделения Российской академии медицинских наук (ГУ НИИ онкологии ТНЦ СО РАМН) Способ радионуклидной диагностики рака молочной железы
DK2245464T3 (en) 2008-01-25 2017-02-20 Multivir Inc P53 BIOMARKETS
US8314068B2 (en) * 2008-04-14 2012-11-20 University Hospitals Of Cleveland P2X7 inhibition of epithelial cancers and papillomas
EP2300023A2 (en) * 2008-05-16 2011-03-30 Genelux Corporation Microorganisms for preventing and treating neoplasms accompanying cellular therapy
EP2370582B1 (en) 2008-12-04 2017-05-10 CuRNA, Inc. Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene
RU2384845C1 (ru) * 2008-12-18 2010-03-20 ФГУП Государственный научно-исследовательский институт особо чистых биопрепаратов ФМБА Способ диагностики онкологических заболеваний
MX2011007980A (es) * 2009-02-02 2011-08-17 Okairos Ag Secuencias de acido nucleico y aminoacido de adenovirus de simio, vectores que contienen los mismos y usos de las mismas.
US9050276B2 (en) 2009-06-16 2015-06-09 The Trustees Of Columbia University In The City Of New York Autism-associated biomarkers and uses thereof
RU2395234C1 (ru) * 2009-07-24 2010-07-27 Учреждение Российской Академии Наук Институт Молекулярной Биологии Им. В.А. Энгельгардта Ран (Имб Ран) ОПРЕДЕЛЕНИЕ СНИЖЕНИЯ УРОВНЯ мРНК ГЕНА ZG16 КАК СПОСОБ ДИАГНОСТИКИ РАКА ТОЛСТОЙ КИШКИ И НАБОР ДЛЯ ЕГО ОСУЩЕСТВЛЕНИЯ
CN108404115A (zh) 2010-10-15 2018-08-17 纽约市哥伦比亚大学理事会 肥胖症-相关的基因和它们的蛋白和其用途
EP2635299B1 (en) 2010-11-02 2019-07-31 The Trustees of Columbia University in the City of New York Methods for treating hair loss disorders
WO2012142529A2 (en) 2011-04-15 2012-10-18 Genelux Corporation Clonal strains of attenuated vaccinia viruses and methods of use thereof
CN102352368B (zh) * 2011-09-29 2013-12-04 苏州大学 Ing4与osm双基因共表达载体及其应用
US9175312B2 (en) * 2011-12-08 2015-11-03 Virovek Incorporation Vectors harboring toxic genes, methods and uses therefor
CN104169850B (zh) 2012-01-12 2017-06-06 辛纳普蒂克斯公司 单层电容性成像传感器
NZ627528A (en) * 2012-02-15 2016-05-27 Aileron Therapeutics Inc Peptidomimetic macrocycles
US10039777B2 (en) 2012-03-20 2018-08-07 Neuro-Lm Sas Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
KR102135601B1 (ko) 2012-03-29 2020-07-20 더 트러스티스 오브 콜롬비아 유니버시티 인 더 시티 오브 뉴욕 탈모 질환의 치료 방법
EP2968551B1 (en) 2013-03-15 2021-05-05 The Trustees of Columbia University in the City of New York Fusion proteins and methods thereof
EP2978454A1 (en) * 2013-03-27 2016-02-03 Ge Healthcare As Method and reagent for preparing a diagnostic composition
ES2878549T3 (es) * 2013-06-18 2021-11-19 Dnatrix Inc Adenovirus oncolítico para su uso en el tratamiento del cáncer cerebral
US9542023B2 (en) 2013-08-07 2017-01-10 Synaptics Incorporated Capacitive sensing using matrix electrodes driven by routing traces disposed in a source line layer
US20150091842A1 (en) 2013-09-30 2015-04-02 Synaptics Incorporated Matrix sensor for image touch sensing
US9298325B2 (en) 2013-09-30 2016-03-29 Synaptics Incorporated Processing system for a capacitive sensing device
US10042489B2 (en) 2013-09-30 2018-08-07 Synaptics Incorporated Matrix sensor for image touch sensing
US9459367B2 (en) 2013-10-02 2016-10-04 Synaptics Incorporated Capacitive sensor driving technique that enables hybrid sensing or equalization
US9274662B2 (en) 2013-10-18 2016-03-01 Synaptics Incorporated Sensor matrix pad for performing multiple capacitive sensing techniques
US9081457B2 (en) 2013-10-30 2015-07-14 Synaptics Incorporated Single-layer muti-touch capacitive imaging sensor
US9682123B2 (en) 2013-12-20 2017-06-20 The Trustees Of Columbia University In The City Of New York Methods of treating metabolic disease
US9798429B2 (en) 2014-02-28 2017-10-24 Synaptics Incorporated Guard electrodes in a sensing stack
CN104357408A (zh) * 2014-03-13 2015-02-18 哈尔滨博翱生物医药技术开发有限公司 一种重组新城疫病毒及其应用
US10133421B2 (en) 2014-04-02 2018-11-20 Synaptics Incorporated Display stackups for matrix sensor
US9927832B2 (en) 2014-04-25 2018-03-27 Synaptics Incorporated Input device having a reduced border region
US9690397B2 (en) 2014-05-20 2017-06-27 Synaptics Incorporated System and method for detecting an active pen with a matrix sensor
PL3201234T3 (pl) 2014-09-30 2019-04-30 Diadem S R L Przeciwciało wiążące liniowy epitop ludzkiego p53 i zastosowania diagnostyczne tego przeciwciała
US10175827B2 (en) 2014-12-23 2019-01-08 Synaptics Incorporated Detecting an active pen using a capacitive sensing device
EP3925979A3 (en) 2014-12-23 2022-03-23 The Trustees of Columbia University in the City of New York Fgfr-tacc fusion proteins and methods thereof
US10990148B2 (en) 2015-01-05 2021-04-27 Synaptics Incorporated Central receiver for performing capacitive sensing
US9939972B2 (en) 2015-04-06 2018-04-10 Synaptics Incorporated Matrix sensor with via routing
US10095948B2 (en) 2015-06-30 2018-10-09 Synaptics Incorporated Modulation scheme for fingerprint sensing
US9715304B2 (en) 2015-06-30 2017-07-25 Synaptics Incorporated Regular via pattern for sensor-based input device
US9720541B2 (en) 2015-06-30 2017-08-01 Synaptics Incorporated Arrangement of sensor pads and display driver pads for input device
CN205028263U (zh) 2015-09-07 2016-02-10 辛纳普蒂克斯公司 一种电容传感器
US10037112B2 (en) 2015-09-30 2018-07-31 Synaptics Incorporated Sensing an active device'S transmission using timing interleaved with display updates
US10067587B2 (en) 2015-12-29 2018-09-04 Synaptics Incorporated Routing conductors in an integrated display device and sensing device
CN106933400B (zh) 2015-12-31 2021-10-29 辛纳普蒂克斯公司 单层传感器图案和感测方法
WO2018071814A1 (en) 2016-10-14 2018-04-19 The Trustees Of Columbia University In The City Of New York Methods of treating alcohol abuse disorder
RU2760993C1 (ru) * 2021-02-15 2021-12-02 Сергей Александрович Никитин Способ рентгеновской терапии рака легких

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4740463A (en) * 1984-04-13 1988-04-26 Massachusetts Institute Of Technology Methods and artificial genes for antagonizing the function of an oncogene
ZA858044B (en) * 1984-11-01 1987-05-27 American Home Prod Oral vaccines
US4748022A (en) * 1985-03-25 1988-05-31 Busciglio John A Topical composition
US4822605A (en) * 1986-02-18 1989-04-18 Exovir, Inc. Compositions and methods employing the same for the treatment of viral and cancerous skin lesions and the like
US5055400A (en) * 1986-11-26 1991-10-08 University Of Guelph Leukotoxin gene of pasteurella haemolytica
US5166320A (en) * 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
US4980289A (en) * 1987-04-27 1990-12-25 Wisconsin Alumni Research Foundation Promoter deficient retroviral vector
US5532220A (en) * 1987-08-31 1996-07-02 The Regents Of The University Of California Genetic mechanisms of tumor suppression
US5017524A (en) * 1989-02-13 1991-05-21 Iscar Ltd. Ceramic cutting tool
US5362623A (en) * 1991-06-14 1994-11-08 The John Hopkins University Sequence specific DNA binding by p53
US6800617B1 (en) * 1989-03-29 2004-10-05 The Johns Hopkins University Methods for restoring wild-type p53 gene function
US5527676A (en) * 1989-03-29 1996-06-18 The Johns Hopkins University Detection of loss of the wild-type P53 gene and kits therefor
US6677312B1 (en) * 1989-03-29 2004-01-13 The Johns Hopkins University Methods for restoring wild-type p53 gene function
US5328470A (en) * 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5585362A (en) * 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
WO1992015680A1 (en) * 1991-03-06 1992-09-17 Board Of Regents, The University Of Texas System Methods and compositions for the selective inhibition of gene expression
US6410010B1 (en) * 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
US5747469A (en) * 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
US5252479A (en) * 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
FR2688514A1 (fr) * 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
US5496731A (en) * 1993-03-25 1996-03-05 Xu; Hong-Ji Broad-spectrum tumor suppressor genes, gene products and methods for tumor suppressor gene therapy
TW442569B (en) * 1993-10-25 2001-06-23 Canji Inc Recombinant adenoviral vector
WO1995034671A1 (en) * 1994-06-10 1995-12-21 Genvec, Inc. Complementary adenoviral vector systems and cell lines

Also Published As

Publication number Publication date
CA2238829A1 (en) 1997-06-05
US20060035857A1 (en) 2006-02-16
US20020077313A1 (en) 2002-06-20
PL186018B1 (pl) 2003-09-30
CN1207771A (zh) 1999-02-10
SK70598A3 (en) 1999-04-13
RU2174409C2 (ru) 2001-10-10
AU722042B2 (en) 2000-07-20
CZ296810B6 (cs) 2006-06-14
NO982481D0 (no) 1998-05-29
JP2000501394A (ja) 2000-02-08
DE69636120T2 (de) 2006-11-30
DE69636120D1 (de) 2006-06-14
PL327009A1 (en) 1998-11-09
CN1308450C (zh) 2007-04-04
CN101028523A (zh) 2007-09-05
HUP9902068A3 (en) 2001-02-28
EP0863984A1 (en) 1998-09-16
EP0863984B1 (en) 2006-05-10
WO1997020047A1 (en) 1997-06-05
NO982481L (no) 1998-07-29
US20030166603A1 (en) 2003-09-04
ATE325872T1 (de) 2006-06-15
DK0863984T3 (da) 2006-08-28
KR19990071795A (ko) 1999-09-27
NZ324168A (en) 2004-11-26
HUP9902068A2 (hu) 1999-10-28
CZ165798A3 (cs) 1998-12-16
AU1126397A (en) 1997-06-19

Similar Documents

Publication Publication Date Title
ES2264145T3 (es) Metodos y composiciones para el tratamiento de cancer.
ES2160707T5 (es) Composiciones que comprenden agentes deteriorantes del adn y p53.
US6326356B1 (en) Suppression of neu overexpression using a mini-E1A gene
US6251871B1 (en) P16 expression constructs and their application in cancer therapy
US6172212B1 (en) Pea3 is a tumor suppressor
US6482803B1 (en) Modification of mutated P53 gene in tumors by retroviral delivery of ribozyme A
US7163925B1 (en) p16 expression constructs and their application in cancer therapy
EP1724350A1 (en) Method and compositions for the diagnosis and treatment of cancer
HK1100393A (en) Method and compositions for the diagnosis and treatment of cancer